Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the vaccine components to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pegu, Poonam, Vaccari, Monica, Gordon, Shari, Keele, Brandon F., Doster, Melvin, Guan, Yongjun, Ferrari, Guido, Pal, Ranajit, Ferrari, Maria Grazia, Whitney, Stephen, Hudacik, Lauren, Billings, Erik, Rao, Mangala, Montefiori, David, Tomaras, Georgia, Alam, S. Munir, Fenizia, Claudio, Lifson, Jeffrey D., Stablein, Donald, Tartaglia, Jim, Michael, Nelson, Kim, Jerome, Venzon, David, Franchini, Genoveffa
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2013
Sujets:
Vaccines and Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554145/
https://ncbi.nlm.nih.gov/pubmed/23175374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02544-12
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires